Skip to content

Prospective non-randomized controlled study of Tuire Formula in the treatment of influenza

Clinical Study on the Efficacy of Professor Liu Qingquans Self-Formulated Tuire Formula in the Treatment of Influenza

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001653
Enrollment
Unknown
Registered
2025-09-03
Start date
2019-04-10
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Control Group:Standard treatment + Oseltamivir Phosphate Capsules
Intervention Group:Standard treatment + Oseltamivir Phosphate Capsules + Tuire Formula

Sponsors

Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for this study were as follows: patients with a disease duration of =36 hours a body temperature of =38 ? at least one respiratory symptom (cough sore throat or rhinitis) accompanied by at least one systemic symptom (headache myalgia sweating or chills or fatigue) a positive influenza virus nucleic acid test and an age between 18 and 60 years. In addition all patients were required to be fully informed and to voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: The exclusion criteria for this study were as follows: pregnant or postpartum women; patients with psychiatric disorders or those unable or unwilling to cooperate; individuals who had received influenza vaccination within the past 12 months; those who had participated in other clinical trials within the past 3 months; patients currently receiving systemic corticosteroids or other immunosuppressive agents; individuals with significant chronic diseases or human immunodeficiency virus (HIV) infection; those with a history of alcohol or drug abuse; and patients who had already received antiviral or antibiotic treatment for influenza.

Design outcomes

Primary

MeasureTime frame
Median symptom relief time for seven influenza symptoms (nasal congestion, sore throat, cough, myalgia, fatigue, headache, and fever or sweating);

Secondary

MeasureTime frame
Median time to fever resolution;Median time to cough resolution;Total influenza symptom score;Total dosage of ibuprofen usage;Proportion of patients developing common complications within 48 hours after enrollment and treatment (common complications include otitis media, bronchitis, sinusitis, and pneumonia);Proportion of patients with common complications who received antibiotic treatment;

Countries

China

Contacts

Public ContactLiu Qing Quan

Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China

surui114@126.com13260397833

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026